Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies, marking a significant step forward in precision oncology.
The partnership aims to combine Telix’s expertise in radiopharmaceutical development, including its global manufacturing capabilities and supply chain infrastructure, with Regeneron’s strengths in biologics and antibody discovery. In particular, the collaboration will leverage Regeneron’s proprietary antibody portfolio derived from its VelocImmune® platform to target multiple solid tumor types.
Radiopharmaceutical therapies represent an emerging class of cancer treatments that deliver targeted radiation directly to tumor cells, minimizing damage to surrounding healthy tissue. By integrating biologics-based targeting mechanisms with radiopharmaceutical delivery, the companies aim to create highly precise and effective treatment options for patients with hard-to-treat cancers.
As part of the agreement, the two companies will also co-develop diagnostic tools to support patient selection and monitor treatment responses. These radio-diagnostic assets are expected to play a key role in advancing personalized medicine approaches, ensuring that therapies are tailored to the specific characteristics of each patient’s disease.
John Lin highlighted the importance of expanding therapeutic approaches in oncology, noting that targeted radiopharmaceuticals represent a promising frontier in cancer treatment. He emphasized that the collaboration aligns with Regeneron’s strategy of exploring diverse modalities, including monoclonal antibodies, bispecific antibodies, and cell therapies.
Israel Lowy added that the partnership enables Regeneron to enter the radiopharmaceutical space while exploring opportunities to combine these therapies with its existing immuno-oncology platforms. He pointed to areas of high unmet need, such as lung cancer, where innovative treatment combinations could significantly improve patient outcomes.
From Telix’s perspective, Christian Behrenbruch described the collaboration as a unique opportunity to advance next-generation biologics-based radiopharmaceuticals, leveraging complementary capabilities across both organizations.
Financially, the agreement includes an upfront payment of $40 million from Regeneron to Telix, granting access to its radiopharmaceutical manufacturing platform for four initial therapeutic programs. Regeneron also has the option to expand the collaboration to include four additional programs, subject to further payments. The companies will share global commercialization costs and profits equally, with Telix retaining the option to co-promote certain products.
Alternatively, for programs where Telix opts out of co-funding, the company may receive up to $535 million in development and commercial milestone payments, along with low double-digit royalties on future sales.
The collaboration underscores growing industry interest in radiopharmaceuticals as a next frontier in oncology, combining precision targeting with potent therapeutic effects to address cancers that remain difficult to treat with existing approaches.